Dermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies

Dermata Therapeutics chairman and CEO Gerald Proehl takes Proactive's Stephen Gunnion through the clinical-stage biotechnology company's pipeline of treatments focused on medical and aesthetic skin conditions.

He says the company's lead candidate DMT310 will move into Phase 3 studies once it gets the go-ahead from the US Food and Drug Administration (FDA) - a major milestone for Dermata. The acne treatment is the first product candidate being developed from the company's Spongilla technology platform.

DMT410 uses its Spongilla technology as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com